Medulloblastoma: From molecular subgroups to molecular targeted therapies

79Citations
Citations of this article
164Readers
Mendeley users who have this article in their library.

Abstract

Brain tumors are the leading cause of cancer-related death in children, and medulloblastoma (MB) is the most common malignant pediatric brain tumor. Advances in surgery, radiation, and chemotherapy have improved the survival of MB patients. But despite these advances, 25-30% of patients still die from the disease, and survivors suffer severe long-term side effects from the aggressive therapies they receive. Although MB is often considered a single disease, molecular profiling has revealed a significant degree of heterogeneity, and there is a growing consensus that MB consists of multiple subgroups with distinct driver mutations, cells of origin, and prognosis. Here, we review recent progress in MB research, with a focus on the genes and pathways that drive tumorigenesis, the animal models that have been developed to study tumor biology, and the advances in conventional and targeted therapy.

Cite

CITATION STYLE

APA

Wang, J., Garancher, A., Ramaswamy, V., & Wechsler-Reya, R. J. (2018, July 8). Medulloblastoma: From molecular subgroups to molecular targeted therapies. Annual Review of Neuroscience. Annual Reviews Inc. https://doi.org/10.1146/annurev-neuro-070815-013838

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free